The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

The Cardiac Dimensions Carillon Mitral Contour System is a minimally invasive mitral regurgitation therapy made possible by ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Bhubaneswar: The Kalinga Institute of Medical Sciences (KIMS) is leading the way in Odisha by offering complex heart ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

This month: shorter recovery after TAVI, Down syndrome CV insights, the benefits of brisker walking, and more.

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

The following is a summary of "Novel Right Ventricular Function Parameters Can Identify Short-Term Non-Responders To ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...